Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01320553 · ClinicalTrials.gov registry record · Phase 2
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
A Phase 2 study of Allergic Conjunctivitis, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
- 1
- Study location
NCT01320553 is a Phase 2 study of Allergic Conjunctivitis that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 122 participants, roughly in line with the 129-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT01320553, a Phase 2 study of Allergic Conjunctivitis, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
- 1
- Study location
Study Summary
The present study will test if administration of different concentrations of 1334H eyedrops will be effective in treatment of allergic conjunctivitis in people with 10 yrs of age or older.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG SPARC1102 I
- DRUG SPARC1102 II
- DRUG SPARC1102 III
Study Locations (1)
Massachusetts
- ORA Inc - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01320553
The ClinicalTrials.gov registry entry for NCT01320553 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 129-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target. The listed sponsor is Sun Pharma Advanced Research Company Limited, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 4 interventions - of which Vehicle is the first listed.
NCT01320553 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01320553 about?
NCT01320553 is a clinical study titled "Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis". The present study will test if administration of different concentrations of 1334H eyedrops will be effective in treatment of allergic conjunctivitis in people with 10 yrs of age or older.
What is the current status of trial NCT01320553?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2011-06. Estimated completion is 2011-09.
What conditions does trial NCT01320553 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT01320553?
The interventions under investigation include: Vehicle (DRUG), SPARC1102 I (DRUG), SPARC1102 II (DRUG), SPARC1102 III (DRUG).
Who is sponsoring clinical trial NCT01320553?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01320553 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation
COMPLETED · Phase 2
-
Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
COMPLETED · Phase 2
-
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
COMPLETED · Phase 2
-
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.